IRLAB Therapeutics AB (publ) (STO:IRLAB.A)
Sweden · Delayed Price · Currency is SEK 1.690
+0.058 (3.55%)
At close: Feb 10, 2026
IRLAB Therapeutics AB Revenue
IRLAB Therapeutics AB had revenue of 18.85M SEK in the quarter ending September 30, 2025, with 108.69% growth. This brings the company's revenue in the last twelve months to 85.56M, up 69.03% year-over-year. In the year 2024, IRLAB Therapeutics AB had annual revenue of 94.63M with 1,566.57% growth.
Revenue (ttm)
85.56M
Revenue Growth
+69.03%
P/S Ratio
1.68
Revenue / Employee
2.76M
Employees
31
Market Cap
143.55M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 94.63M | 88.95M | 1,566.57% |
| Dec 31, 2023 | 5.68M | -55.46M | -90.71% |
| Dec 31, 2022 | 61.14M | -146.65M | -70.58% |
| Dec 31, 2021 | 207.78M | 207.48M | 69,160.67% |
| Dec 31, 2020 | 300.00K | -72.00K | -19.35% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Xbrane Biopharma AB | 259.70M |
| Sprint Bioscience AB | 50.03M |
| Alligator Bioscience AB | 46.22M |
| NextCell Pharma AB | 11.06M |
| Biovica International AB | 9.89M |
| Simris Group AB (PUBL) | 2.30M |
| Biosergen AB | 527.00K |